Licence and Product Supply Agreement with Tristel
Byotrol plc ("Byotrol" or the "Company")
Know-How Licence and Product Supply Agreement with Tristel plc
Byotrol is pleased to announce a new collaboration ("the Agreement") with fellow infection prevention and control specialists Tristel plc.
The Agreement relates to three specific technologies
1. A concentrated surface disinfectant initially targeted for use in hospitals, dispensed from Tristel's proprietary Cache system of innovative packaging solutions; and
2. A concentrated surface disinfectant with long-lasting (8 hour) anti-microbial efficacy also to be dispensed from Tristel's proprietary Cache system. This product is a concentrate version of ACTIZONE, a Solvay technology developed in conjunction with Byotrol; and
3. A unique surface disinfectant combining Tristel's proprietary sporicidal chemistry, with Byotrol's long-lasting anti-microbial technology, also based on the ACTIZONE technology platform. The combined product will speedily eliminate spores on application, and will then remain active against microbes for an 8-hour period after application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8".
The Agreement has a duration of 10 years and will be exclusive in hospitals in the UK and Ireland and non-exclusive elsewhere. Under the terms of the Agreement, Tristel will pay to Byotrol a combination of product supply payments, royalties and fees, based on success but with meaningful minimum guarantee payments to Byotrol each year.
David Traynor, Chief Executive of Byotrol, said:
"We are really pleased to be working with Tristel in this way and are particularly pleased that our chemistries now work in combination, with genuinely unique new product claims at a key time in infection control. This agreement now brings our products to many more customers in healthcare and beyond, and in formats that we could not do on our own"
Enquiries:
Byotrol plc
David Traynor - Chief Executive Officer
Nic Hellyer - Chief Financial Officer 01925 742 000
finnCap
Geoff Nash/ Richard Chambers - Corporate Finance 020 7220 0500
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and control technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.
Powerful, long-lasting and gentle, Byotrol's products can be used stand-alone or as ingredients within existing products, where Byotrol can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Founded in 2005, the Company develops technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to www.byotrol.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 1 minute ago Aurrigo International
- 25 minutes ago Savills
- 45 minutes ago Everyman Media Group
- 1 hour ago Croda International
- 2 hours ago Diageo